Loading organizations...
Beijing-based Galixir develops artificial intelligence technologies to accelerate preclinical drug discovery and development for hard-to-target diseases and unmet clinical needs. The company utilizes its proprietary Pyxir platform, which integrates computational chemistry, medicinal chemistry, and biology, alongside deep learning frameworks like TankBind to predict molecular binding and model drug interactions. Their research pipeline primarily targets complex conditions across autoimmune, central nervous system, respiratory, and metabolic diseases, as well as various cancers. To support its ongoing research and development efforts, Galixir has raised $10 million in total funding through multiple venture rounds backed by institutional investors including Gaorong Capital, 5Y Capital, Bertelsmann Investments, and DCM Ventures. The enterprise continues to expand its pipeline and collaborate with pharmaceutical firms, recently nominating a preclinical candidate for an autoimmune disease. Galixir was founded in 2019 by Chengtao Li.
Galixir has raised $10.0M across 1 funding round.
Galixir has raised $10.0M in total across 1 funding round.
Galixir has raised $10.0M in total across 1 funding round.
Galixir's investors include 5Y Capital, Asylum Ventures, Preface Ventures, Source Code Capital.
Galixir has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Seed in August 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2020 | $10M Seed | — | 5Y Capital, Asylum Ventures, Preface Ventures, Source Code Capital | Announced |
Galixir is a biotech company founded in 2019 that leverages artificial intelligence to accelerate preclinical drug discovery, focusing on analyzing molecular structures via deep learning to optimize drug development processes.[1][2] It supports R&D for generic and new drugs by optimizing chemical synthesis pathways, reducing manufacturing time and costs, and providing pharmaceutical companies with faster drug discovery methods and strong patent protections.[1][3] Currently at Series B stage and headquartered in Haidian, Beijing, China, Galixir employs around 117 people and generates under $5 million in revenue, serving the healthcare and pharmaceutical industries.[1][2]
Galixir was established in 2019 in Beijing, China, as a medical research firm applying advanced AI technologies, particularly multimodal deep learning on known molecular structures, to empower preclinical drug R&D workflows.[1][2] While specific founders are not detailed in available sources, the company has a co-founder serving as Chief Operating Officer, indicating a leadership team with operational expertise in AI-driven biotech.[2] Early momentum includes strategic collaborations, such as with DoubleRainbow Biosciences to advance drug discovery using AI, highlighting pivotal partnerships that bolster its growth in the competitive AI-biotech space.[2]
Galixir rides the wave of AI integration in drug discovery, a trend transforming biotech by repurposing known compounds and accelerating R&D amid rising demand for faster, cheaper therapies.[1] Its timing aligns with global pushes for AI in healthcare, where traditional drug development's high failure rates (over 90%) and costs (often billions per drug) create tailwinds for innovators like Galixir that cut timelines via machine learning.[1][2] Market forces favoring it include China's booming biotech sector, explosive growth in AI pharma tools, and partnerships with firms like DoubleRainbow Biosciences, positioning Galixir to influence ecosystem-wide adoption of AI for rare diseases and generics.[1][2] By competing with players like Stonewise and Healx, it contributes to a collaborative landscape lowering barriers for pharma innovation.[1]
Galixir's Series B status and recent Mosaic Score dip signal a maturing player navigating funding dynamics, with potential for expansion through more AI collaborations and global pharma deals.[1][2] Upcoming trends like multimodal AI advancements and regulatory nods for AI-discovered drugs could propel its growth, evolving its role from preclinical enabler to full-cycle drug innovator. As AI reshapes biotech, Galixir stands poised to deliver breakthrough efficiencies, tying back to its core mission of faster, smarter drug development that saves time, costs, and lives.[1][2][3]
